Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Cerianna (fluoroestradiol F18) is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-3]
• The FES PET imaging demonstrated a pooled detection rate of 0.80 for breast cancer and 0.84 for ovarian cancer. The FES SUV mean for endometrial cancer was reported between 3.4-5.3, which is higher compared to breast cancer (2.05) and uterine sarcoma (1.1-2.6).
• F-18 FES PET/CT exhibited a sensitivity of 0.86 and a specificity of 0.85 in assessing estrogen receptor expression in patients with recurrent or metastatic breast cancer.
• FES PET imaging and [¹⁸F]FDG PET imaging had similar detection rates for breast and ovarian cancer, with FES thresholds detecting 11.1% to 45% of ER heterogeneity, particularly effective in uterine cancer prognosis.
• The safety profile of F-18 FES PET/CT was primarily marked by injection site pain, attributed to mechanical injury from the needle, with no significant adverse effects reported related to the radioactive material.
• There is no population type or subgroup information available in the reviewed studies.